Florida State University
College of Law
Building, Room #
J.D., Vanderbilt Law School, 2015
M.D., Tufts University School of Medicine, 2011
B.A., Amherst College, 2000
Dr. Mason Marks is the Florida Bar Health Law Section Professor at Florida State University College of Law. He is the senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and an affiliated fellow at the Information Society Project at Yale Law School. Marks was previously a resident fellow at the Edmond J. Safra Center for Ethics at Harvard University, a research scholar at the Information Law Institute at NYU Law School, and a visiting fellow at Yale Law School.
Marks's academic research focuses on health technology, FDA regulation, and constitutional law. He is particularly interested in state and federal controlled substance regulation, health privacy, and the application of artificial intelligence to medical decision making. His academic writing has been published or is forthcoming in the Duke Law Journal, the Harvard Law Review Forum, the Boston University Law Review, UC Irvine Law Review, the UC Davis Law Review, the Administrative Law Review, the Yale Journal of Law and Technology, the NYU Journal of Legislation and Public Policy, and books by Cambridge University Press.
In addition to legal scholarship, Marks writes about law and technology for publications such as The Washington Post, the Los Angeles Times, The Guardian, The Seattle Times, Slate, WIRED, Vice News, Gizmodo, STAT News, and the Houston Chronicle. His legal commentary has been featured by The New York Times, The Wall Street Journal, The Washington Post, ABC News, Fox News, Bloomberg News, the Telegraph, Radio Boston, German Public Radio, and NPR's All Things Considered.
At Florida State University, Marks teaches Constitutional Law, Drug Law, and Legislation and Regulation. In addition to teaching and research, he is an attorney of council at the international law firm Harris Bricken. An expert on the fast-emerging psychedelics industry, he has presented his research at the Food and Drug Administration, the Department of Health and Human Services, and the National Academies of Sciences, Engineering, and Medicine.
Marks has advised city, state, and federal officials on the rapidly evolving regulatory landscape regarding psychedelics. He served as a founding member of the Oregon Psilocybin Advisory Board, where he chaired the Licensing Subcommittee, and drafted psychedelics legislation adopted by the Washington State Legislature and the Seattle City Council.
Select Recent and Forthcoming Publications
Microdosing Under State and Federal Law, with I. Glenn Cohen, __ Boston University Law Review __ (forthcoming 2023)
Automating FDA Regulation, 71 Duke Law Journal 101 (forthcoming 2022)
Patents on Psychedelics: The Next Legal Battlefront of Drug Development, 135 Harvard L. Rev. F. 212 (2022)
Biosupremacy: Big Data, Antitrust, and Monopolistic Power Over Human Behavior, 55 U.C. Davis L. Rev. 995 (forthcoming 2022)
Emergent Medical Data: Health Information Inferred by Artificial Intelligence, 11 U.C. Irvine L. Rev. 995 (2021)
Psychedelic Therapies: A Roadmap for Wider Acceptance and Utilization, with I. Glenn Cohen, 27 Nature Medicine 1669 (2021)
Controlled Substance Regulation for the COVID-19 Mental Health Crisis, 72 Admin. L. Rev. 649 (2020)
Artificial Intelligence Based Suicide Prediction, 21 Yale J. L. & Tech. 98 (2019)